title: Endoscopic balloon dilatation for benign fibrotic strictures after curative nonsurgical treatment for esophageal cancer.
abstract: BACKGROUND
  Endoscopic balloon dilatation (EBD) is performed to treat strictures after esophagectomy. However, little is known about using EBD for benign strictures that occur after nonsurgical treatments for esophageal cancer such as chemoradiotherapy (CRT) or endoscopic mucosal resection (EMR). The aim of this study was to evaluate the safety and efficacy of EBD for benign strictures after nonsurgical treatment compared with those after surgery.
  
  
  METHODS
  We identified 823 patients with esophageal cancer who completed definitive treatments between 2004 and 2007. Of these patients, 122 were enrolled in our study, including 60 who had surgery and 62 who did not have surgery (32 CRT, 30 EMR). The indication criteria for EBD were complaint of dysphagia and the inability to pass a conventional endoscope due to benign stricture. We retrospectively analyzed the safety and efficacy of EBD, and the measured outcomes were treatment success rate, time to treatment success, and refractory stricture rate.
  
  
  RESULTS
  Perforation occurred in 3 (0.3 %) of 1,077 EBD sessions, with no bleeding. Efficacy was evaluated in 110 of the 122 patients. While the treatment success rate was over 90 % in both the surgery and the nonsurgery group, there was a significant difference in the median time to treatment success between both groups (2.3 vs. 5.6 months, p = 0.02: log-rank test). There was a significant difference in the median time to treatment success between CRT and surgery groups (7.0 months, p = 0.01), with no significant difference in the EMR group (4.4 months, p = 0.85). A significant difference in the refractory stricture rate was evident between the nonsurgery group (75 %) and the surgery group (45 %, p < 0.01).
  
  
  CONCLUSIONS
  EBD for stricture after nonsurgical treatment of esophageal cancer was safe and effective. However, patients with benign strictures after nonsurgical treatment required significantly longer time to recover from dysphasia compared to those after surgery.
authors.affiliation: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwanoha 6-5-1, Kashiwa, Chiba, 277-8577, Japan. yuyoda@east.ncc.go.jp
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Yoda
authors.forename: Tomonori
authors.initials: T
authors.lastname: Yano
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Kaneko
authors.forename: Shinya
authors.initials: S
authors.lastname: Tsuruta
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Oono
authors.forename: Takashi
authors.initials: T
authors.lastname: Kojima
authors.forename: Keiko
authors.initials: K
authors.lastname: Minashi
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ikematsu
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ohtsu
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000628:therapy; D003680:Deglutition Disorders / Q000209:etiology / Q000517:prevention & control*; D004106:Dilatation / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D004724:Endoscopy / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D004869:Equipment Safety; D004938:Esophageal Neoplasms / Q000628:therapy*; D004939:Esophageal Perforation / Q000209:etiology; D004940:Esophageal Stenosis / Q000209:etiology / Q000628:therapy*; D016629:Esophagectomy / Q000009:adverse effects; D004947:Esophagus / Q000473:pathology; D005260:Female; D005355:Fibrosis / Q000209:etiology / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016879:Salvage Therapy
chemical_list: D000970:Antineoplastic Agents